Nomura Asset Management Co. Ltd. Has $11.45 Million Position in Insulet Corporation $PODD

Nomura Asset Management Co. Ltd. lessened its stake in Insulet Corporation (NASDAQ:PODD) by 75.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 36,449 shares of the medical instruments supplier’s stock after selling 113,022 shares during the quarter. Nomura Asset Management Co. Ltd. owned 0.05% of Insulet worth $11,452,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Semanteon Capital Management LP purchased a new position in shares of Insulet during the 2nd quarter valued at $274,000. Generali Investments Management Co LLC purchased a new stake in shares of Insulet during the second quarter worth $55,000. Citizens Financial Group Inc. RI boosted its position in Insulet by 34.4% during the second quarter. Citizens Financial Group Inc. RI now owns 1,169 shares of the medical instruments supplier’s stock valued at $367,000 after purchasing an additional 299 shares during the last quarter. Cetera Investment Advisers grew its stake in Insulet by 80.9% in the second quarter. Cetera Investment Advisers now owns 11,677 shares of the medical instruments supplier’s stock valued at $3,669,000 after purchasing an additional 5,222 shares in the last quarter. Finally, Creative Planning grew its stake in Insulet by 1.6% in the second quarter. Creative Planning now owns 8,408 shares of the medical instruments supplier’s stock valued at $2,642,000 after purchasing an additional 136 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms recently commented on PODD. BTIG Research restated a “buy” rating and issued a $370.00 price objective on shares of Insulet in a report on Thursday, November 13th. Wolfe Research boosted their target price on shares of Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Jefferies Financial Group increased their price target on shares of Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Zacks Research raised shares of Insulet from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $376.35.

Insider Activity at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.39% of the stock is currently owned by company insiders.

Insulet Stock Performance

NASDAQ:PODD opened at $346.36 on Thursday. The firm’s 50-day moving average is $322.93 and its 200-day moving average is $314.19. The company has a market cap of $24.37 billion, a price-to-earnings ratio of 105.28, a PEG ratio of 2.64 and a beta of 1.39. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet Corporation has a 52-week low of $230.05 and a 52-week high of $353.50.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. During the same period last year, the business earned $1.08 earnings per share. The firm’s revenue for the quarter was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.